Winhealth is a China-based, Asia Pacific centric, innovative biotechnology company, providing novel breakthrough therapies to patients with rare diseases and other unmet medical needs. Winhealth primarily focused on licensing in novel breakthrough therapies from leading global biopharma companies, to serve patients with rare diseases and other unmet medical needs in the region. The company is headquartered in Hong Kong, with operating hubs in Hangzhou, Shanghai, and Beijing. The company owns China’s first rare disease managed access platform in Bo’ao, Hainan. The company also has representative offices in Japan, Singapore and Europe. Winhealth has built a unique, balanced and diversified portfolio with numerous innovative rare disease and specialty products at commercial and late clinical stages, some with blockbuster potential. The company is also continuously looking to bring in more innovative therapies from the globe.